Showing results (1-10 of 113) with videos related to
Sort By:
Pageof 12
Frontiers in Endocrinology|June 21, 2012
The Pathogenic Role of the Adaptive Immune Response to Modified LDL in DiabetesGabriel Virella, Maria F Lopes-VirellaJournal of Atherosclerosis and Thrombosis|August 23, 2013
Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosisMaria F Lopes-Virella, Gabriel VirellaCurrent Medicinal Chemistry|May 25, 2018
Modified LDL Immune Complexes and Cardiovascular DiseaseMaria F Lopes-Virella, Gabriel VirellaAtherosclerosis|June 3, 2008
Atherogenesis and the humoral immune response to modified lipoproteinsGabriel Virella, Maria F Lopes-VirellaFrontiers in Bioscience : a Journal and Virtual Library|September 6, 2003
The role of immune and inflammatory processes in the development of macrovascular disease in diabetesMaria F Lopes-Virella, Gabriel VirellaClinical Immunology (Orlando, Fla.)|May 12, 2009
Clinical significance of the humoral immune response to modified LDLMaria F Lopes-Virella, Gabriel VirellaClinical Immunology (Orlando, Fla.)|July 27, 2016
F(ab')2 fragments of anti-oxidized LDL IgG attenuate vascular inflammation and atherogenesis in diabetic LDL receptor-deficient miceYanchun Li, Zhongyang Lu, Yan Huang, et al.Journal of Diabetes and Its Complications|February 11, 2016
High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetesMaria F Lopes-Virella, Kelly J Hunt, Nathaniel L Baker, et al.Journal of Lipid Research|May 6, 2003
LDL immune complexes stimulate LDL receptor expression in U937 histiocytes via extracellular signal-regulated kinase and AP-1Yuchang Fu, Yan Huang, Sumita Bandyopadhyay, et al.Diabetes Care|March 30, 2004
Role of simvastatin as an immunomodulator in type 2 diabetesMaria F Lopes-Virella, Marina Mironova, Elias Stephan, et al.Pageof 12